PharVision Advisers’s Arteris AIP Stock Holding History

PharVision Advisers’s Portfolio AIP Stock Details AIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,655	Closed	-$320K	–	112
2025 Q4	$320K	Buy	+20,655	New	+$299K	0.16%	235
2025 Q1	–	Sell	-17,013	Closed	-$173K	–	272
2024 Q4	$173K	Buy	+17,013	New	+$141K	0.15%	332

Other funds holding AIP

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Samjo Management New York $231M AUM 13.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PharVision Advisers's AIP Position: Q1 2026 in Review

PharVision Advisers sold out of Arteris (AIP) in Q1 2026, closing a stake of 20,655 shares — an estimated $320K sold.

PharVision Advisers first reported a position in AIP in Q4 2024 and held it in 2 quarters. The position peaked at $320K in Q4 2025. 152 funds tracked by Wall St. Rank hold AIP as of Q1 2026.

PharVision Advisers reported no remaining Arteris position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 20,655 Arteris shares in Q1 2026, an estimated $320K.
PharVision Advisers first reported a position in Arteris in Q4 2024 and held it in 2 quarters.
PharVision Advisers's Arteris position peaked at $320K in Q4 2025.
152 funds tracked by Wall St. Rank held Arteris as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.